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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: In LMCA stenosis without signiﬁcant aorto-ostial stenosis, both stra-
tegies of with or without aorto-ostial coverage showed similar clinical outcomes at 2
years.
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Background: Changes in revascularization strategies and outcomes among patients
with signiﬁcant unprotected left main coronary artery (LMCA) stenosis remain largely
unknown.
Methods: A total of 2618 consecutive patients with LMCA stenosis undergoing
revascularization treatment between 1995 and 2010 were identiﬁed from ASAN
MAIN registry. Patients were classiﬁed into three periods: bare metal stent (WAVE1)
period(1995-1998), early drug-eluting stent (WAVE2) period(2003-2006), and late
drug-eluting stents (WAVE3)period (2007-2010). The major adverse cerebro-car-
diovascular events (MACCE) were deﬁned as death, myocardial infarction, repeat
revascularization, or stroke at 2-years.
Results: The major adverse cerebro-cardiovascular events (MACCE) were deﬁned as
death, myocardial infarction, repeat revascularization, or stroke at 2-years.During
study periods, 1124 patients underwent percutaneous coronary intervention (PCI) with
stent and 1494 patients underwent coronary artery bypass grafting (CABG). The
proportion of PCI signiﬁcantly increased from 35% to 52%. Among patients receiving
PCI, the risk-adjusted incidence rate of MACCE decreased from 20.18 cases per 100
person-years in WAVE1 to 6.77 cases per 100 person-years in WAVE3 (P< 0.001 for
trend). Death, the composite of death, myocardial infarction, or stroke, and repeat
revascularization were also signiﬁcantly decreased by 40%, 35%, and 46%, respec-
tively. However, among patients receiving CABG, the risk-adjusted incidence rate of
MACCE was not signiﬁcantly changed during study period. In addition, the difference
in the risk of MACCE between PCI and CABG progressively reduced (adjusted
hazard ratio [95% conﬁdence interval]: 0.33 [0.23-0.47], 0.53 [0.35-0.80], and 1.01
[0.68-1.49] from WAVE1 through WAVE3.
Conclusions: The outcomes of PCI for LMCA stenosis have signiﬁcantly improved
and PCI has successfully substituted CABGin a signiﬁcant proportion of patients with
LMCA stenosis.
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Background: The aim of this study was to assess efﬁcacy and safety proﬁle of distal
LM stenosis treatment with dedicated bifurcation BiOSS stents (Balton, Poland): inB66 JACC Vol 64/11/Suppl B jgroup I - paclitaxel-eluting BiOSS Expert and in group II - sirolimus-eluting BiOSS
LIM.
Methods: Patients with CAD or NSTE-ACS were enrolled between January 2011 and
June 2013 in three centers in Bulgaria, Poland and Spain. Decision for LM stenting
was based on Heart Team consensus. Provisional T-stenting was default strategy.
Control angiography was planned at 12 months in all patients. The primary end point
is MACE at 12 months. Here, we present 6-month clinical data from both groups and
completed angiographic data from BiOSS Expert. At the time of TCT 2014 angio-
graphic data from BiOSS LIM will be completed.
Results: There were enrolled 158 patients (62 in BiOSS Expert group and 96 in
BiOSS LIM group). The average age was 65.712.5 yrs and 19.7% were female. In
the study 17.8% of patients were with NSTE-ACS, 73.4% with hypertension, 81.4%
with dyslipidemia, 32.1% with diabetes, 39.2% with prior MI, 43.3% with prior PCI
and 17.4% with prior CABG. The mean SYNTAX score was 21.526.58. True bi-
furcations were treated in 70.1% of cases. All BiOSS stents were implanted suc-
cessfully. The nominal stent parameters were as followed: BiOSS Expert group:
4.070.26mm (proximal diameter) x 3.360.26mm (distal diameter) x 16.611.72
mm (length) and BiOSS LIM group: 3.900.4mm x 3.170.39mm x
16.812.06mm. Classical DES in side branch was implanted in 25.9% and 21.4%,
respectively. Almost 62% of procedures were done from radial access and 83% with
6F catheter. After 12 months in BiOSS Expert group angiographically-driven TLR
rate was 9.6%, whereas clinically-driven TLR was 3.2%. In BiOSS LIM group data
are pending - at 6 months there were no death or MI. In BiOSS Expert group late
lumen loss was as follows: in main vessel - 0.210.1mm, in main branch –
0.260.12mm and in side branch – 0.140.09mm.
Conclusions: Dedicated bifurcation BiOSS stents seem feasible devices with prom-
ising effectiveness and safety proﬁle in distal LM stenosis. Complete BiOSS LIM data
facilitate to answer the question if the used drug or stent design is more crucial.
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Background: Final kissing balloon inﬂation (FKBI) is a mandatory technique in un-
protected left main (ULM) revascularization with 2-stent strategy. However, there is no
consensus regarding the necessity of FKBI in single-stent strategy. Therefore, to assess
the need of FKBI for single-stent strategy in ULM lesion, we compared clinical outcome
between patients treated using single-stent strategy with FKBI and those without FKBI.
Methods: A total of 654 consecutive patients who had ULM lesion were treated using
drug-eluting stent between April 2005 and August 2010. Of these, 470 patients were
eligible in this study after exclusion of 21 patients with ostial ULM and 163 patients
treated using 2-stent strategy. In patients using single-stent strategy, 357 patients were
proceeded with FKBI (FKBI group) and 113 patients were without FKBI (no-FKBI
group). The end point of this study is the occurrence of Major Adverse Cardiovascular
Event (MACE) deﬁned as composites of all cause death, target lesion revasculariza-
tion (TLR) and MI. Furthermore, overall TLR, TLR for main branch (TLR-MB)
involving ULM to left anterior descending artery and TLR for side branch alone
(TLR-SB) involving left circumﬂex (LCx) at 1-year were evaluated.
Results: Patient and lesion characteristics were similar between the 2 groups.
Following single-stent strategy, 36 patients (8.9%) necessitated an additional bailout
stenting for ostial LCx stenosis. In the total population, the occurrence of MACE at 1
year is similar between the two groups (7.4% in the FKBI group and 11.9% in the no
FKBI group, log rank p¼0.112). The incidences of overall TLR, TLR-MB and TLR-
SB at 1 year were also similar between FKBI group vs. no-FKBI group (7.0% vs.
9.3%, p¼0.44, 2.5% vs. 4.7%, p¼0.24 and 5.0% vs.5.6%, p¼0.81, retrospectively).
Conclusions: Single-stent for ULM disease was feasible at mid-term follow-up.
However, FKBI had no impact on clinical outcome following ULM revascularization
with Single-stent strategy.
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Background: Unprotected left main coronary artery (ULMCA) stenting has been
investigated as an alternative to coronary artery bypass grafting (CABG). However,
long-term beneﬁts of PCI or CABG in patients with ULMCA disease and severe left
ventricular dysfunction (LVD) have not been established.
Methods: Between March 1992 to February 2011, a total of 213 patients with sig-
niﬁcant ULMCA disease and severe LVD (ejection fraction [EF] of 40% or less) who
underwent PCI (42 patients) or CABG (171 patients) were identiﬁed from ASAN
MAIN Registry. Primary endpoint was all-cause death at 2 years.September 13–17, 2014 j TCT Abstracts/Coronary Lesions - Left Main
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMResults: Pre-procedural EF was not different between two groups (34.3  5.9 vs. 32.4
 6.2%, P¼0.10). The CABG group included more patients with triple-vesseldisease
(P< 0.001) and the PCI group included more patients with presenting with myocardial
infarction (MI) (P¼0.002). At 2 years, death occurred in 7 (17.1%) of the PCI group
and 27 (15.7%) of the CABG group (P¼0.73). The composite of death, MI or stroke
occurred in 8 (19.5%) of the PCI group and 30 (17.4%) of the CABG group (P¼0.63).
The rates of target-vessel revascularization were signiﬁcantly higher in the PCI group
(4.9% vs. 0%, P¼0.003). After adjustment for the baseline characteristics, hazard ratio
was 0.94 (95% CI, 0.39w2.23; P¼0.88) for death; 0.99 (95% CI, 0.44w2.23;
P¼0.98) for the death, MI, or stroke; 186.6 (95% CI, contain 0; P¼0.58) for target-
vessel revascularization.
Conclusions: In patients with ULMCA disease and severe LVD, PCI and CABG
showed similar clinical outcomes at 2 year follow-up.
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Background: Percutaneous coronary intervention (PCI) for unprotected left main
trunk (ULMT), especially with single stent strategy, has favorable outcome with
advent of drug eluting stent (DES). Direct comparison of the outcome between PCI
with single stent strategy for ULMT bifurcation lesion and left anterior descending
artery (LAD) is lacking. The aim of this study is to testify the long-term feasibility of
PCI for ULMT bifurcation lesion with single stent strategy by comparison with LAD
lesion.
Methods:We investigated retrospectively 105 consecutive patients (mean age: 69.3
years old, female: 21.0% and diabetes mellitus: 38.1%) who were treated by siro-
limus eluting stent (SES) implantation with single stent strategy for ULMT bifur-
cation disease from August 2004 to December 2010 in our center. We compared
them with a matched group of 105 patients who underwent SES implantation for
LAD lesion with the same strategy. Matching criteria was identical age, gender and
presence of diabetes mellitus. All the cases were done with intravascular ultrasound
guidance. We assessed occurrence of MACE (a composite of cardiac death, non-
fatal acute myocardial infarction (AMI) and target lesion revascularization (TLR)),
cardiac death, AMI, stent thrombosis and TLR. Mean follow-up period was
65.328.4 months.
Results: There were no statistical differences in MACE and other endpoints between
the two groups (Figure). A favorable trend for ULMT lesion was shown in MACE
(p¼0.09).Conclusions: DES implantation with single stent strategy for ULMT bifurcation
lesion provides as feasible long-term outcome as for LAD lesion.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CoTCT-229
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Background: Clinical outcomes after treatment of ostial/midshaft lesions in unpro-
tected left main coronary artery (ULMCA) with ﬁrst generation drug-eluting stents
(DES) have been found to be favorable. However, to date, data regarding new gen-
eration DES for these lesion subsets have not been reported. The aim of this study was
to compare the clinical outcomes following ULMCA percutaneous coronary inter-
vention (PCI) of ostial/midshaft lesions with ﬁrst versus new generation DES.
Methods: A total of 219 patients from the Milan New-Tokyo (MITO) registry with
ostial/midshaft lesions in ULMCA treated with ﬁrst (n¼139) or new generation DES
(n¼80) were analyzed.
Results: The ﬁrst generation DES group had more males (78.4% vs. 63.8%,
p¼0.026). There was a higher prevalence of IVUS use (35.2% vs. 50.0%, p¼0.032)
and post-dilation (70.5% vs. 93.8%, p < 0.001) with larger maximum balloon
diameter (3.810.45 vs. 4.080.44, p < 0.001) in the new generation DES group. At
a median follow-up period of 730 days, there were no signiﬁcant differences in the
propensity-score adjusted analyses, for major adverse cardiac events (MACE) deﬁned
as composite endpoint of all-cause death, myocardial infarction and target vessel
revascularization (HR [new vs. ﬁrst generation DES]: 1.22; 95% CI: 0.64 to 2.31;
p¼0.549). Of note, target lesion revascularization rates at 2-years were only 0.9% and
2.7%, for ﬁrst and new generation DES groups, respectively (p¼0.339). On multi-
variable analysis, SYNTAX score (HR: 1.06; 95% CI: 1.02-1.11, p¼0.006) and
EuroSCORE (HR: 1.14; 95% CI: 1.00-1.31, p¼0.051) were independent predictors
for MACE.
Conclusions: This study suggests that new generation DES for ostial/midshaft lesions
in ULMCA are associated with favorable clinical outcomes, comparable to those
observed with ﬁrst generation DES.
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Background: Percutaneous coronary intervention (PCI) with drug eluting stent
(DES) implantation for left main coronary artery (LMCA) stenosis has been shown
to be a feasible and safe approach. However, optimal stenting technique is still
under discussion. Our goal is to evaluate safety and efﬁcacy of novel stenting
technique in LM distal lesions - intravascular ultrasound (IVUS) guided and op-
tical coherence tomography (OCT) optimized everolimus eluting platinum chro-
mium stent (SYNERGY) and bioresorbable coronary scaffold (ABSORB)
implantation.
Methods: 31 patient with distal LMCA are enrolled in ongoing study at Latvian
Center of Cardiology. All interventions were IVUS guided and OCT optimized.
Plaque modiﬁcation with cutting balloon before stenting was performed. SYNERGY
stent was implanted across the CX followed by ABSORB implantation at the proximal
CX. Procedure is ﬁnished with “kissing” post-dilation. 12-month angiographic, IVUS
and OCT follow-up is ongoing.
Results: All patients underwent the procedure due to stable angina, 25 (81%) of them
were males. Mean patient age was 6211 years, 26 (85%) of them were hypertonic
with dyslipidemia, 7 (23%) suffered from diabetes mellitus and were smokers. Mean
SYNTAX score 27,62,6. Synergy stent length implanted in LM-LAD was 236,53
mm, diameter 3,750,27mm. Mean Absorb scaffold length implanted in LM-LCX
was 163,10 mm, diameter 3,20,52 mm. Stenting technique: modiﬁed T stenting 10
cases, mini – Crush 21.There were no procedural complications. No major cardiac
adverse events occurred during hospitalization period and 30 day follow-up.
Conclusions: The current study demonstrates that novel LMCA stenting technique
using SYNERGY stent and ABSORB scaffold is safe and feasible. No seriousronary Lesions - Left Main B67
